Survival predictors in patients treated with a molecular adsorbent recirculating system

Table 2 Demographic, clinical, and treatment data at the beginning of MARS treatment

Characteristic	All patients	ALF			AOCLF		Graft failure
		Toxic	Unknown cause	Other	Alcohol-related	Other
Number of patients	192	63	41	9	45	17	11
Age, years	49 (14-81)	41 (14-81)	51 (19-68)	43 (32-58)	52 (30-71)	54 (16-75)	47 (18-62)
Sex, % male (n)	48 (93)	48 (30)	32 (13)	33 (3)	69 (31)	47 (8)	36 (4)
Body mass index, kg/m2	26 (17-56)	24 (17-40)	28 (19-37)	28 (23-34)	27 (18-46)	27 (20-56)	27 (19-56)
MARS sessions/patient	2 (1-13)	2 (1-8)	3 (1-12)	3 (1-9)	2 (1-13)	2 (1-9)	2 (1-4)
Duration of MARS session, h	16.5 (4-22.5)	15.0 (5.5-22)	16.8 (4-22)	16.0 (6.4-22)	20.1 (7.8-22)	18.3 (4.5-22.5)	17.5 (9.5-22)
Mechanically ventilation used, % (n)	36 (69)	29 (18)	34 (14)	56 (5)	29 (13)	41 (7)	73 (8)
Vasoactive-medications used, % (n)	43 (82)	33 (21)	27 (11)	33 (3)	47 (21)	82 (14)	63 (7)
Renal insufficiency, % (n)	49 (94)	33 (21)	37 (15)	44 (4)	60 (27)	76 (13)	73 (8)
MELD score	32 (5-52)	27 (5-48)	32 (23-50)	27 (23-46)	39 (17-52)	36 (27-44)	26 (20-47)
Mean encephalopathy grade before treatment (± SD)	1.8 (1.5)	1.6 (1.6)	2.0 (1.4)	2.4 (1.7)	1.5 (1.4)	1.9 (1.6)	2.0 (1.9)
Mean encephalopathy grade after treatment (± SD)	1.4 (1.6)	1.4 (1.7)	1.5 (1.7)	1.4 (1.6)	1.1 (1.5)	1.9 (1.8)	1.3 (1.7)
P	< 0.001	NS	0.05	0.04	0.02	NS	0.059

All demographic values are expressed as median (range) or percentage of patients (number of patients). Encephalopathy grades are expressed as mean ± SD). NS: Non-significant.